From Standard of Care
←Older revision | Newer revision→
Used for prophylaxis and treatment of pneumocystis jiroveci.
Adverse reactions occur in 8% of patients.
3.3% of patients have hypersensitivity reactions.
In HIV patients adverse reactions and hypersensitivity reactions occur with much higher frequency and can be as history as 50%.
Proposed that a metabolite hydroxylamine may accumulate, along with a deficiency of glutathione in patients with HIV may increase toxicity in HIV infected patients.